Effects of oral administration of Bifidobacterium animalis subsp. lactis HN019 on the treatment of plaque-induced generalized gingivitis.
Bifidobacterium lactis
Gingivitis
Probiotics
Journal
Clinical oral investigations
ISSN: 1436-3771
Titre abrégé: Clin Oral Investig
Pays: Germany
ID NLM: 9707115
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
14
02
2022
accepted:
02
10
2022
pubmed:
29
10
2022
medline:
28
1
2023
entrez:
28
10
2022
Statut:
ppublish
Résumé
This double-blind, randomized, placebo-controlled clinical trial evaluated the adjuvant effects of Bifidobacterium lactis HN019 on the treatment of plaque-induced generalized gingivitis. Sixty patients were submitted to professional supragingival scaling and prophylaxis. They were randomly assigned to test (probiotic lozenges containing B. lactis HN019, n = 30) or control (placebo lozenges, n = 30) groups. Lozenges were consumed twice a day for 8 weeks. Bleeding on probing (BoP), Gingival Index (GI), Plaque Index (PI), probing depth (PD), and clinical attachment level (CAL) were evaluated at baseline and after 2 and 8 weeks. Gingival crevicular fluid (GCF) was collected at baseline and at 8 weeks for analysis of the inflammatory mediators IL-1β, IL-1α, IL-8, MCP-1, and MIP-1β. Data were statistically analyzed (p < 0.05). After 8 weeks, both groups showed reduction in the percentage of PI, with no significant difference between groups (p = 0.7423). The test group presented a lower percentage of BoP and a higher percentage of sites with GI ≤ 1 when compared with the control group at the end of the study (p < 0.0001). At 8 weeks, the test group had a greater number of patients without generalized gingivitis than the control group (20 and 11 patients, respectively; p < 0.05). The test group presented significantly lower levels of IL-1α, IL-1β, and MCP-1 in GCF than the control group at the end of the study (p < 0.05). The adjunct use of B. lactis HN019 promotes additional clinical and immunological benefits in the treatment of generalized gingivitis. B. lactis HN019 can be an efficient and side-effect-free adjunct strategy in the treatment of generalized gingivitis.
Identifiants
pubmed: 36305963
doi: 10.1007/s00784-022-04744-y
pii: 10.1007/s00784-022-04744-y
pmc: PMC9614197
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Pagination
387-398Informations de copyright
© 2022. The Author(s).
Références
Contemp Clin Dent. 2017 Jan-Mar;8(1):116-121
pubmed: 28566862
Periodontol 2000. 2021 Jun;86(1):201-209
pubmed: 33690926
Periodontol 2000. 2021 Oct;87(1):254-267
pubmed: 34463979
J Oral Microbiol. 2010 Nov 02;2:
pubmed: 21523225
J Indian Soc Periodontol. 2018 Sep-Oct;22(5):414-418
pubmed: 30210190
Periodontol 2000. 2021 Jun;86(1):113-122
pubmed: 33690989
J Clin Periodontol. 2005 Aug;32(8):880-5
pubmed: 15998272
J Periodontal Res. 2017 Jun;52(3):497-504
pubmed: 27859252
Oral Dis. 2022 May;28(4):1058-1067
pubmed: 33772970
PLoS One. 2017 Jun 29;12(6):e0179946
pubmed: 28662142
Acta Odontol Scand. 2009;67(1):19-24
pubmed: 18985460
Infect Drug Resist. 2020 Feb 26;13:659-672
pubmed: 32161474
J Clin Periodontol. 2022 Feb;49(2):111-122
pubmed: 34818686
Eur J Orthod. 2015 Jun;37(3):297-307
pubmed: 25246605
Cell. 2018 Sep 6;174(6):1388-1405.e21
pubmed: 30193112
Acta Odontol Scand. 1963 Dec;21:533-51
pubmed: 14121956
Angle Orthod. 2021 Mar 1;91(2):220-226
pubmed: 33378447
Braz Oral Res. 2022 May 02;36:e062
pubmed: 36507749
J Clin Periodontol. 2018 Jun;45 Suppl 20:S68-S77
pubmed: 29926499
Benef Microbes. 2018 Apr 25;9(3):487-494
pubmed: 29264967
J Dent. 2016 May;48:16-25
pubmed: 26965080
J Periodontol. 2017 Feb;88(2):197-208
pubmed: 27660886
Tandlaegebladet. 1976 Mar;80(5):149-52
pubmed: 1078196
J Clin Periodontol. 2012 Aug;39(8):736-44
pubmed: 22694350
Benef Microbes. 2018 Jun 15;9(4):593-602
pubmed: 29633646
J Indian Soc Periodontol. 2015 Nov-Dec;19(6):633-9
pubmed: 26941513
Br J Nutr. 2000 Feb;83(2):167-76
pubmed: 10743496
J Clin Periodontol. 2009 Oct;36(10):850-6
pubmed: 19682173
Int J Dent Hyg. 2021 Nov;19(4):398-406
pubmed: 33768685
Appl Microbiol Biotechnol. 2019 Aug;103(16):6463-6472
pubmed: 31267231
J Periodontal Res. 2017 Apr;52(2):225-232
pubmed: 27093564
J Dent Res. 2004 Oct;83(10):786-90
pubmed: 15381720
Aust Dent J. 2020 Mar;65(1):12-20
pubmed: 31682012
J Periodontol. 2017 Nov;88(11):1115-1123
pubmed: 28753102
Oxid Med Cell Longev. 2019 May 2;2019:1607304
pubmed: 31191794
Cochrane Database Syst Rev. 2013 Dec 05;(12):CD010514
pubmed: 24310847
J Clin Periodontol. 2016 Nov;43(11):948-954
pubmed: 27461133
Periodontol 2000. 2021 Oct;87(1):315-324
pubmed: 34463980
J Am Dent Assoc. 2006 Dec;137(12):1649-57
pubmed: 17138709
J Clin Periodontol. 2015 Nov;42(11):1032-41
pubmed: 26427036
J Indian Soc Periodontol. 2009 Sep;13(3):150-4
pubmed: 20379413
J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2 Suppl 1):197-202
pubmed: 28691473
J Clin Periodontol. 2010 Apr;37(4):324-33
pubmed: 20447255
J Dent Res. 2007 Feb;86(2):125-30
pubmed: 17251510
PLoS One. 2020 Sep 22;15(9):e0238425
pubmed: 32960889
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Acta Odontol Scand. 2013 May-Jul;71(3-4):828-33
pubmed: 23294143
J Clin Periodontol. 2017 Jul;44(7):708-716
pubmed: 28556062
J Periodontol. 2022 Feb;93(2):e1-e12
pubmed: 34374081
J Periodontol. 2014 Jul;85(7):975-83
pubmed: 24171503
J Clin Periodontol. 2019 Jul;46(7):723-739
pubmed: 31058336
Swed Dent J. 2006;30(2):55-60
pubmed: 16878680
Periodontol 2000. 2021 Oct;87(1):17-31
pubmed: 34463986
J Clin Periodontol. 2018 Oct;45(10):1198-1210
pubmed: 30076613
J Oral Sci. 2011 Sep;53(3):263-71
pubmed: 21959652
Ann Med. 2016;48(4):246-55
pubmed: 27092975
J Clin Periodontol. 2004 Dec;31(12):1029-33
pubmed: 15560802
Med Princ Pract. 2020;29(5):492-498
pubmed: 32241014
Eur J Clin Nutr. 2011 Jul;65(7):857-63
pubmed: 21448219